Pursuant to Regulation 44 of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015, please find enclosed the Scrutinizer''s Report on the business transacted at the Extraordinary ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Sudarshan Pharma Industries held an Extraordinary General Meeting (EGM) on June 12, 2025 via video conferencing, where all 15 resolutions were passed with 100% votes in favor. The two special resolutions granted the board authority to borrow money and create charges/mortgages up to Rs. 2,500 Crores. The remaining 13 ordinary resolutions approved related-party transactions with multiple subsidiaries (Singapore, Ratna Lifesciences, Ishwari Healthcare, Sudarshan Maven Pharma, Life Science Chemical, Sudarshan Pharma Lifescience) and related parties (Sudarshan Solvents, Sachin Chemsolve, Sudarshan Capital, Magicremedi, Sudarshan Chempharma India LLP, Sudarshan Akshar Specialty Chemicals LLP, M/s Sachin Chemicals). The cut-off date was June 5, 2025, with 1,331 total shareholders; 18 attended via VC, 29 voted remotely, and 1 voted at the EGM.
Shareholders have approved a very large borrowing ceiling of Rs. 2,500 Crores, signaling potential expansion plans or major capital needs ahead. All related-party transactions were cleared without opposition, meaning inter-group dealings between the company and its subsidiaries/group entities can proceed smoothly for the next fiscal year.